Sinopharm Group Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Sinopharm Group Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sinopharm Group Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sinopharm Group Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sinopharm Group Co Ltd (Sinopharm), a subsidiary of China National Pharmaceutical Group Corp, distributes pharmaceutical and healthcare products. The company offers distribution, logistics, and other value-added services to pharmaceutical, medical, and healthcare product manufacturers and suppliers both domestically and internationally. It serves hospitals, primary health service institutions, and retail drug stores. Sinopharm also manufactures and sells pharmaceuticals, chemical reagents, laboratory supplies and carries out the development of pharmaceuticals, medical services, and other health-related industries. The company manages a chain of medicine stores in China through direct operations and franchises to market pharmaceutical and healthcare products. Sinopharm is headquartered in Shanghai, China.
Headquarters
China
Address
Sinopharm Group Building, No. 385, East Longhua Road, Shanghai, 200051
Website
www.sinopharmgroup.com.cn
Telephone
86 21 23052666
No of Employees
94,910
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1099 (HKG)
Revenue (2024)
$80.0B
-1.6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
1.5%
(2024 vs 2023)
Market Cap*
$6.9B
Net Profit Margin (2024)
XYZ
2.5%
(2024 vs 2023)
* As of and is in US$
Sinopharm Group Co Ltd premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Chemical Reagents | Pharmaceutical and Healthcare Products Distribution and Logistics |
| Laboratory Supplies | Retail Drug Stores |
| Medical Equipment | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In May, the company entered into an agreement with Buchang Pharma, to deepen strategic cooperation, enhance drug commercialization, optimize logistics, and expand health services. |
| 2026 | Contracts/Agreements | In April, the company entered into an agreement with Senshi Haiya to enhance market penetration of herbal medicines, improve drug accessibility, and jointly build a sustainable pharmaceutical supply chain, supporting the Healthy China strategy and industry transformation. |
| 2025 | Contracts/Agreements | In December, the company signed an agreement to acquire a 70% stake in Shanghai Zenith Pharmaceutical Technology Co. |
Competitor Comparison
| Key Parameters | Sinopharm Group Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | China Resources Sanjiu Medical & Pharmaceutical Co Ltd | Tasly Pharmaceutical Group Co Ltd | Wai Yuen Tong Medicine Holdings Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | Hong Kong |
| City | Shanghai | Shanghai | Shenzhen | Tianjin | Hong Kong City |
| State/Province | Shanghai | Shanghai | Guangdong | Tianjin | - |
| No. of Employees | 94,910 | 40,603 | 30,304 | 10,563 | 726 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jin Bin | Chairman | Executive Board | 2025 | 52 |
| Li Xiaojuan | Chief Financial Officer | Senior Management | 2021 | 49 |
| Chen Qiyu | Vice Chairman | Executive Board | 2010 | 53 |
| Lian Wanyong | Director; President | Executive Board | 2024 | 55 |
| Yang Binghua | Director | Executive Board | 2025 | 45 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer